Trop-2 expression in carcinoma of the uterine cervix (CX) – a possible target for the treatment approach with antibody drug conjugates (ADC)

Background The Trophoblast Cell Surface Antigen 2 (TROP-2) is associated with invasiveness and tumor progression in several malignancies (Cubas et al. 2010, Wang et al. 2008). Strong TROP-2-expression is associated with poor prognosis in cervical carcinoma (Liu et al. 2013). Recently, TROP-2 was identified as a target protein for treatment of solid tumors using antibody-drug conjugates (ADC; Bardia et al. 2021b, Coates et al. 2021). The data for the expression of Trop2 in CXis limited (Liet al. 2013, Dum et al. 2022)